Printer Friendly
The Free Library
19,573,952 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

CEO INTERVIEW: ROGER NEWTON - ESPERION THERAPEUTICS INC (ESPR).


(PAL205) ROGER NEWTON - ESPERION THERAPEUTICS INC (ESPR ESPR European Society of Paediatric Radiology
ESPR Espressivo (music)
ESPR Ethnicity and Social Policy Research Unit (University of Bradford)
ESPR European Society of Paediatric Research
). Describes the company's business and its background; prospects for the industry, with positive and negative trends; competitive threats; strategic opportunities for the firm including its marketing plans and acquisition potential; management strength and organization; and the financial prospects of the firm looking forward. Sector: Biotechnology. Published date 6/2/02. Tickers featured: ESPR. Complete text approximately 3000 words. Document # PAL205.

CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board.  INTERVIEWS, The Wall Street Transcript, 67 Wall Street, NY 10005. Voice (212) 952 7433. Fax: (212) 668-9842. E-mail: transcript@twst.com.

***
COPYRIGHT 2002 Wall Street Transcript Corporation
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2002 Gale, Cengage Learning. All rights reserved.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Comment:CEO INTERVIEW: ROGER NEWTON - ESPERION THERAPEUTICS INC (ESPR).(Brief Article)
Publication:Wall Street Transcript Digest
Article Type:Brief Article
Geographic Code:1USA
Date:Jun 10, 2002
Words:89
Previous Article:CEO INTERVIEW: MARK SKALETSKY - ESSENTIAL THERAPEUTICS INC (ETRX).
Next Article:[0] CEO INTERVIEW: MICHAEL HART - ALLOS THERAPEUTICS INC (ALTH).
Topics:



Related Articles
L. WILLIAM MCINTOSH - NEXELL THERAPEUTICS INC (NEXL).
Canaan Partners Continues Investment Momentum in Healthcare Market; Five IPO and Other Liquidity Events Reflect Healthcare Market Rebound.
ANALYST INTERVIEW: EMERGING BIOTECHNOLOGY COMPANIES:MARK MONANE - NEEDHAM & CO.
Esperion Invites You to Participate in Its Second Quarter 2002 Conference Call.
Esperion Announces June 26 Conference Call to Review Initial ETC-216 -AIM- Phase II Trial Results.
ANALYST INTERVIEW: THERAPEUTICS-BASED COMPANIES: MARK SCHOENEBAUM - U.S. BANCORP PIPER JAFFRAY INC.
Eleventh United States patent issued for Esperion's peptide program.
CEO INTERVIEW: ROGER NEWTON - ESPERION THERAPEUTICS INC (ESPR).

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles